Chemotherapy and integrin α2β1 in the plasma of osteosarcoma patients

Objective Integrin α2β1 is a member of the integrin family,which is found to play an important role in the pathogenesis and progression of tumor.This study aimed to investigate the effect of chemotherapy on integrin α2β1 in the plasma of osteosarcoma patients,and to explore the clinical significance of integrin α2β1 and its prospects in the diagnosis and treatment of osteosarcoma.Methods We collected plasma samples from osteosarcoma patients before and after chemotherapy,and detected the levels of integrin α2β1 in the plasma by ELISA.Results The level of integrin α2β1 in the plasma was(1.73±0.56) μg/L after the chemotherapy,significantly reduced in comparison with(2.41±0.77) μg/L before the chemotherapy(P0.01).Conclusion Chemotherapy can decrease the level of integrin α2β1 in the plasma of osteosarcoma patients,which suggests that effective chemotherapy may down-regulate the expression of integrin α2β1 and alter the biological activity of osteosarcoma cells.Accordingly integrin could be a plasma marker for the prognosis of chemotherapy for osteosarcoma.